Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults

Hoelzer, Dieter; Thiel, Eckhard; Löffler, Helmut; Bodenstein, H.; Plaumann, L.; Büchner, Th.; Urbanitz, D.; Koch, P.; Heimpel, Hermann; Engelhardt, R.

doi:10.1182/blood.v64.1.38.38

Cited by 270 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD56 was positive in three patients with AML, and these patients also expressed CD7. Treatment protocols consisted of intermediate dose Ara‐C and daunorubicine in patients with AML and protocol for German Multicentre Study Group for Adult ALL (GMALL‐1988) and intensive induction, consolidation and maintenance chemotherapy in patients with ALL (14–16). CR was achieved in nine patients (41%) (five ALL and four AML).…”

Section: Resultsmentioning

confidence: 99%

The importance of CD7 and CD56 antigens in acute leukaemias

Tiftik

Bolaman

Batun

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

The prognostic significance of immunophenotypical properties of leukaemic cells is well known. However, the biological and clinical significance of CD7 and CD56 antigen expression in acute leukaemias are not clearly established. In patients with acute leukaemias, we identified CD7 and CD56 expression and analysed their associations with markers expressed early in haemopoietic ontogeny and clinical parameters. Among 22 patients with acute leukaemia [12 acute myeloblastic leukaemia (AML), 10 acute lymphoblastic leukaemia (ALL)], we found CD7 positivity in 15 of 22 patients (68%) and CD56 positivity in four patients (18%). CD7 positivity was observed in seven patients (58%) with AML and in eight patients (80%) with ALL. CD56 positivity was observed in three patients (25%) with AML and one patient (10%) with ALL. Lymphadenopathy was present in five patients and associated with hepatosplenomegaly in three patients with ALL. Splenomegaly and hepatomegaly were present in three patients with AML. Central nervous system involvement was seen in one patient with ALL. Complete remission was achieved in nine patients (41%) (five ALL and four AML). Our data showed that CD7 and CD56 positivity at diagnosis associated with low remission rate and biological aggressiveness in a significant proportion of patients. We suggest the evaluation of CD7 and CD56 in all patients with acute leukaemias at the time of diagnosis in view of poor clinical outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

The importance of CD7 and CD56 antigens in acute leukaemias

Tiftik

Bolaman

Batun

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Achievement of complete remission within 4 weeks of therapy has been a time‐honoured prognostic factor for adult patients with ALL (Hoelzer et al , 1984) (Table IV). In a report from the German multicentre study for the treatment of ALL, late achievement of CR was found to be the strongest adverse prognostic factor (Hoelzer et al , 1984). Based on this widely accepted concept, time to complete remission was used as initial stratification into risk groups in the MRC UKALL XII/ECOG E2993 study.…”

Section: Prognostic Factors Based On Responsementioning

confidence: 99%

Prognostic factors in adult acute lymphoblastic leukaemia

Rowe

2010

Br J Haematol

118

View full text Add to dashboard Cite

SummaryTreatment of acute lymphoblastic leukaemia (ALL) in adults presents a formidable challenge. While overall results have improved over the past 3 decades, the long-term survival for patients aged less than 60 years is only in the range of 30-40% and is 10-15% if between 60 and 70 years and <5% for those over 70 years. The historic lack of clear-cut biological prognostic factors has led to over-or under-treatment of some patients. Response to initial therapy is an important prognosticator of outcome based on disease biology, as well as pharmacogenetics, which include the patient's response to drugs given. The more widespread availability of allogeneic transplantation and reduced-intensity regimens for older patients have opened up this curative modality to a greater number of patients. Hopefully, those options, as well as novel cytogenetic and molecular markers, will enable a better selection of patients who undergo intensive therapies and finally break the 30-40% cure barrier for adults with ALL.

show abstract

“…The second and third generation schemes such as Macop-B, 7 Promace-CYTAbom 8 and the BFM-83 high-risk protocol 9 were used for high grade groups. CHOP, 10 BACOP 10 and MVPP 11 were used for intermediate groups. For low grade lymphoma, COP 11 and MVPP 11 were the most often used protocols.…”

Section: • Karin Zattar Cecyn • José Salvador Rodrigues De Oliveira •mentioning

confidence: 99%

“…CHOP, 10 BACOP 10 and MVPP 11 were used for intermediate groups. For low grade lymphoma, COP 11 and MVPP 11 were the most often used protocols.…”

Section: • Karin Zattar Cecyn • José Salvador Rodrigues De Oliveira •mentioning

confidence: 99%

Prognostic factors in non-Hodgkin lymphomas

et al. 2000

View full text Add to dashboard Cite

show abstract

Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults

Cited by 270 publications

References 40 publications

The importance of CD7 and CD56 antigens in acute leukaemias

The importance of CD7 and CD56 antigens in acute leukaemias

Prognostic factors in adult acute lymphoblastic leukaemia

Prognostic factors in non-Hodgkin lymphomas

Contact Info

Product

Resources

About